Legal & General Group Plc increased its position in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 7.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,534 shares of the company’s stock after buying an additional 519 shares during the period. Legal & General Group Plc’s holdings in Aerie Pharmaceuticals were worth $396,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. grew its stake in shares of Aerie Pharmaceuticals by 28.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 223,053 shares of the company’s stock valued at $10,115,000 after buying an additional 49,473 shares during the period. BlackRock Inc. boosted its stake in Aerie Pharmaceuticals by 113,376.8% during the 1st quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after purchasing an additional 2,598,596 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in Aerie Pharmaceuticals by 5.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 68,398 shares of the company’s stock valued at $3,102,000 after purchasing an additional 3,739 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Aerie Pharmaceuticals by 64.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 436,955 shares of the company’s stock valued at $22,962,000 after purchasing an additional 171,879 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Aerie Pharmaceuticals by 7.1% during the 1st quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock valued at $63,151,000 after purchasing an additional 92,463 shares during the last quarter. Institutional investors own 94.64% of the company’s stock.

Aerie Pharmaceuticals, Inc. (NASDAQ AERI) opened at 52.65 on Friday. The company’s market capitalization is $1.91 billion. The firm has a 50-day moving average of $54.41 and a 200 day moving average of $50.31. Aerie Pharmaceuticals, Inc. has a 52-week low of $32.05 and a 52-week high of $61.30.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.02. Equities analysts predict that Aerie Pharmaceuticals, Inc. will post ($2.59) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/legal-general-group-plc-raises-stake-in-aerie-pharmaceuticals-inc-aeri/1616781.html.

Several research firms have commented on AERI. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. BidaskClub cut shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $62.00 price target (up previously from $56.00) on shares of Aerie Pharmaceuticals in a report on Thursday, July 20th. Canaccord Genuity reissued a “buy” rating and set a $65.00 target price on shares of Aerie Pharmaceuticals in a report on Monday, July 3rd. Finally, Mizuho reissued a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $66.62.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.